RxDoctor Payments Data

Sarah Bashiruddin, MD

Internal Medicine · Westfield, MANPI 1396192738

Payments from drug & device makers

$533in general payments, 2019–2025

Across 28 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$98
  • Novartis$94
  • E.r. Squibb & Sons, L.L.C.$64
  • Otsuka America Pharmaceutical, Inc.$53
  • Pfizer$49
  • Novo Nordisk$47
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$533 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$611,575
Medicare patients
721
Services billed
9,969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$121,360
EliquisApixaban94$90,040
MounjaroTirzepatide43$48,925
JardianceEmpagliflozin37$45,051
TrulicityDulaglutide24$32,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,821
Breo ElliptaFluticasone/Vilanterol50$23,348
Nurtec OdtRimegepant Sulfate11$22,355
XareltoRivaroxaban26$21,397
FarxigaDapagliflozin Propanediol16$15,862
EntrestoSacubitril/Valsartan12$12,768
JanuviaSitagliptin Phosphate12$12,369
MyrbetriqMirabegron21$11,479
ProtonixPantoprazole Sodium13$10,941
LinzessLinaclotide12$8,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Protonix$49$123,336118 claims
Novo NordiskOzempic$47$121,360119 claims
Lilly USA, LLCMounjaro, Trulicity$98$81,46967 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$19$66,775126 claims
NovartisEntresto$94$12,76812 claims
MerckJanuvia$15$12,36912 claims
AbbVieLinzess$28$8,17312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Westfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →